{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:26:26Z","timestamp":1783193186155,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111078","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:14:39Z","timestamp":1774268079000},"page":"111078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic efficacy of Gemcitabine\/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Gu\u00e9rin induction"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9525-2600","authenticated-orcid":false,"given":"Kaushik P.","family":"Kolanukuduru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Eraky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Chiarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almoflihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.111078_bib0001","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111078_bib0002","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress London 2026. ISBN 978-94-92671-32-5"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111078_bib0003","doi-asserted-by":"crossref","first-page":"443.e1","DOI":"10.1016\/j.urolonc.2025.03.009","article-title":"Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to Bacillus Calmette-Gu\u00e9rin and gemcitabine-docetaxel therapy","volume":"43","author":"Eraky","year":"2025","journal-title":"Urol Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2026.111078_bib0004","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111078_bib0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111078_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111078_bib0007","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00345-025-05613-5","article-title":"Efficacy of Bacillus Calmette-Gu\u00e9rin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer","volume":"43","author":"Eraky","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.111078_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/bju.16827","article-title":"Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs gemcitabine\/docetaxel","author":"Eraky","year":"2025","journal-title":"BJU Int"},{"issue":"5S","key":"10.1016\/j.urolonc.2026.111078_bib0009","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/01.JU.0001109740.05294.af.08","article-title":"IP02-08 comparative efficacy of Bcg induction with Bcg maintenance vs. GEMCITABINE\/docetaxel maintenance in patients with non-muscle-invasive bladder cancer","volume":"213","author":"Kolanukuduru","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111078_bib0010","article-title":"Comparative effectiveness of Bacillus Calmette-Gu\u00e9rin and sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve intermediate-risk non-muscle-invasive bladder cancer","author":"Kolanukuduru","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"5S","key":"10.1016\/j.urolonc.2026.111078_bib0011","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/01.JU.0001008640.01272.9d.19","article-title":"MP16-19 comparison of Bcg to gemcitabine\/docetaxel in the intermediate risk group composed mostly of Tahg","volume":"211","author":"Ben-David","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111078_bib0012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00345-024-04992-5","article-title":"Induction and maintenance of sequential intravesical gemcitabine\/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols","volume":"42","author":"Ben-David","year":"2024","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111078_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination Bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111078_bib0014","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.euf.2023.04.012","article-title":"Comparison of Bacillus Calmette-Gu\u00e9rin maintenance therapy with monthly instillations and the Southwest Oncology Group protocol in the treatment of non-muscle-invasive bladder cancer","volume":"9","author":"Nurminen","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111078_bib0015","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","article-title":"Discontinuance of bacille Calmette-Gu\u00e9rin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence","volume":"73","author":"Takeda","year":"2009","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111078_bib0016","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1464-410X.1998.00890.x","article-title":"Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma","volume":"82","author":"Giannakopoulos","year":"1998","journal-title":"Br J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111078_bib0017","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical Bacillus Calmette Guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients","volume":"23","author":"Derr\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111078_bib0018","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00262-018-2197-x","article-title":"Immunotherapy with cancer peptides in combination with intravesical Bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer","volume":"67","author":"Obara","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"75","key":"10.1016\/j.urolonc.2026.111078_bib0019","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111078_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2026.111078_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2019.00121","article-title":"Combination of intravesical Bacille Calmette-Gu\u00e9rin and chemotherapy vs. Bacille Calmette-Gu\u00e9rin alone in non-muscle invasive bladder cancer: a meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111078_bib0022","doi-asserted-by":"crossref","first-page":"458","DOI":"10.23736\/S2724-6051.24.05777-X","volume":"76","author":"Cicione","year":"2024","journal-title":"Minerva Urol Nephrol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111078_bib0023","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111078_bib0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.juro.2008.03.038","article-title":"Can early single dose instillation of Epirubicin improve Bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study","volume":"180","author":"Cai","year":"2008","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111078_bib0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)68555-2","article-title":"Sequential Bacillus Calmette-Guerin and Epirubicin versus Bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study","volume":"162","author":"Ali-El-Dein","year":"1999","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111078_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2020.08.027","article-title":"Unraveling the mechanism of the antitumor activity of Bacillus Calmette-Gu\u00e9rin","volume":"80","author":"Li","year":"2021","journal-title":"Eur Urol"},{"issue":"4 Suppl 11","key":"10.1016\/j.urolonc.2026.111078_bib0027","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.111078_bib0028","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111078_bib0029","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical Docetaxel and Gemcitabine treatment in BCG-na\u00efve high-grade non-muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:30:31Z","timestamp":1778797831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S107814392600089X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111078","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of Gemcitabine\/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Gu\u00e9rin induction","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111078"}}